{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"LUNAR","nct_id":"NCT05496959","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=lunar-nct05496959. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"LUNAR","arms":[{"description":"Beginning on day 1, patients undergo SBRT to all lesions for 1, 3, or 5 treatment doses (fractions) over the span of 10-20 days in the absence of disease progression or unacceptable toxicity.","label":"Arm 1 (SBRT)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive 177Lu-PNT2002 IV over 1-10 minutes on days -112 and -56 in the absence of disease progression or unacceptable toxicity. Beginning on day 1, patients then undergo SBRT to all lesions for 1, 3, or 5 treatment doses (fractions) over the span of 10-20 days in the absence of disease progression or unacceptable toxicity.","label":"Arm 2 (177Lu-PNT2002, SBRT)","type":"EXPERIMENTAL"}],"collaborators":["Eli Lilly and Company"],"completion_date":{"date":"2033-09-01","type":"ESTIMATED"},"conditions":["Oligometastatic Prostate Carcinoma","Prostate Adenocarcinoma","Recurrent Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":{"count":93,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Lutetium Lu-177 PNT2002","type":"DRUG"},{"name":"Quality-of-Life Assessment","type":"OTHER"},{"name":"Stereotactic Body Radiation Therapy","type":"RADIATION"}],"last_update":"2026-05-26","lead_sponsor":"Jonsson Comprehensive Cancer Center","official_title":"177-Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (Lunar)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2032-09-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Prostate-specific membrane antigen positron emission tomography/computerized tomography (PSMA PET/CT)-based progression-free survival (PFS)","timeFrame":"Time from the date of stereotactic body radiotherapy (SBRT) completion to the date of disease progression or death, whichever happens earlier, assessed up to 24 months"}],"references":[{"citation":"Kishan AU, Valle LF, Wilhalme H, Felix C, Nabong R, Juarez-Casillas JE, Flores K, Ma TM, Ludwig V, Nakayama M, Ells Z, Dahlbom M, Lauria M, Meyer C, Cao M, Weidhaas JB, Telesca D, McGreevy K, Nickols NG, Karasik D, Parmisano S, Basehart TV, Brisbane W, Marks L, Rettig MB, Reiter RE, Boutros PC, Allen-Auerbach M, Czernin J, Steinberg ML, Calais J. 177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study. J Clin Oncol. 2025 Dec 20;43(36):3812-3821. doi: 10.1200/JCO-25-01553. Epub 2025 Nov 12.","pmid":"41223345","type":"DERIVED"}],"start_date":{"date":"2022-09-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study","url":"https://clinicaltrials.gov/study/NCT05496959"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/lunar-nct05496959"}